Website

Zoetis Inc. (ZTS) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 18 wire items for ZTS, including 9 insider trades, 3 SEC filings and 2 analyst ratings. The most recent was published Nov 10, 2026.

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS rankings

Financial highlights

Full financials
Revenue, TTM
$9.49B
Revenue growth
+0.9%
Net income, TTM
$2.51B
Net margin
26.4%
Free cash flow, TTM
$2.23B
Cash
$1.33B

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks62-56%
2026-05-17: 52026-05-24: 32026-05-31: 12026-06-07: 02026-06-14: 12026-06-21: 32026-06-28: 02026-07-05: 12026-07-12: 122026-07-19: 12026-07-26: 02026-08-02: 62026-08-09: 22026-08-16: 02026-08-23: 12026-08-30: 22026-09-06: 02026-09-13: 12026-09-20: 12026-09-27: 12026-10-04: 32026-10-11: 112026-10-18: 22026-10-25: 02026-11-01: 42026-11-08: 1
2026-05-172026-11-08
Mix2890d
  • Insider13(46%)
  • Other6(21%)
  • SEC Filings4(14%)
  • Earnings2(7%)
  • Analyst2(7%)
  • Dividends1(4%)
Activity · 52 weeks18370 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

ZTS FAQ

11 questions
  • What does Zoetis Inc. do?
    Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...
  • What is the latest news on ZTS?
    In the last 30 days Quantisnow tracked 18 wire items for ZTS: 9 insider trades, 3 SEC filings, 2 analyst ratings and 2 press releases and news items. The most recent was published on November 10, 2026.
  • What is ZTS revenue?
    Zoetis Inc. (ZTS) reported $9.49B of revenue for the twelve months ended Sep 30, 2026. That is up 0.9% from the year before. Revenue for fiscal 2025 was $9.47B.
  • Is ZTS profitable?
    Yes. Zoetis Inc. earned $2.51B in net income for the twelve months ended Sep 30, 2026, a net margin of 26.4%.
  • How much cash and debt does ZTS have?
    Zoetis Inc. reported $1.33B in cash and cash equivalents and $9.05B of debt on its most recent balance sheet in SEC filings.
  • Where does ZTS stock trade?
    Zoetis Inc. (ZTS) is listed on NYSE.
  • What sector and industry is ZTS in?
    Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Zoetis Inc. go public?
    Zoetis Inc. (ZTS) completed its IPO in 2013.
  • What are analysts saying about ZTS?
    Across the last 8 analyst actions on Zoetis Inc., there were 0 upgrades and 5 downgrades. The most recent action was from Jefferies: Hold with a $83.00 price target on 2026-10-20. Recent price targets range from $74.00 to $145.00.
  • What companies are similar to ZTS?
    Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare ZTS side-by-side with any of them on Quantisnow.
  • How can I track ZTS on Quantisnow?
    Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.